Earlier vasopressin strategy fails to improve survival in septic shock trial

A hospital strategy recommending earlier addition of vasopressin for septic shock did not significantly improve survival, according to the VASSPR trial published October 14 in JAMA. The findings address a common intensive-care decision: when to add another blood-pressure medicine as initial treatment requirements rise.

The study provides evidence relevant to hospitals caring for critically ill adults, including older patients. It also illustrates why increasing treatment intensity needs testing against outcomes that matter to patients, even when a drug has an established physiological effect.

Testing a treatment strategy in routine care

Intermountain Health researchers studied 3,959 adults across 13 hospitals in Utah and Idaho, with enrollment running from February 2024 through July 2025. Vasopressin helps support blood pressure when the circulation is failing during severe infection. Clinicians have differed over how early to introduce it alongside other vasopressors.

VASSPR used a pragmatic, cluster-randomized crossover design. Hospitals received an initial strategy assignment and then alternated strategies monthly. One recommended adding vasopressin when requirements for other vasopressors reached a lower threshold; the other recommended a higher threshold. Clinical teams retained discretion over individual care.

The median participant age was 68. This makes the trial relevant to an older clinical population, although it was a study of acute illness rather than an investigation of aging biology or lifespan extension.

No significant survival advantage

Death within 28 days, the primary endpoint, occurred in 31.8% of patients assigned to the lower-threshold strategy and 33.0% assigned to the higher-threshold strategy. After adjustment, the estimated risk difference was minus 0.4 percentage points, with a 95% confidence interval ranging from minus 2.7 to plus 1.3 percentage points.

That interval leaves room for a smaller benefit or harm. The result therefore does not establish that the strategies are equivalent.

The key secondary outcome, days free of kidney replacement therapy through day 28, also showed no significant difference. Measures including time alive outside hospital were similar, according to the study and Intermountain’s accompanying account of the findings.

Cardiogenic shock was recorded more often under the lower-threshold strategy. However, this was an exploratory safety signal, and the authors cautioned that multiple comparisons and sensitivity analyses limit its interpretation. It should not be treated as a definitive causal finding.

What the trial can establish

The practical strength of the design is that it tested recommendations within ordinary hospital care. Its limitations follow from the same choice: treatment was unblinded, adherence was imperfect, and crossover could reduce differences between groups.

JAMA’s research summary notes that results might differ with strictly enforced treatment thresholds or alternative approaches. Applicability to less integrated health systems and settings with fewer resources also remains uncertain. Those qualifications matter when translating a hospital policy trial into decisions for an individual patient.

Relevance to survival and healthspan

Sepsis can rapidly damage organs and cause death. CDC identifies it as a medical emergency and reports that most affected people have an underlying medical condition or recent hospitalization. Avoiding severe infection and improving its outcomes are consequently relevant to preserving health across adulthood.

This trial addresses one component of that broader problem. It does not establish that earlier vasopressin improves long-term independence, cognition or functional recovery, and its negative result should not be generalized to delaying sepsis care. CDC continues to emphasize prompt treatment of infection and maintenance of blood flow to organs.

For hospitals, the evidence supplies a concrete test of a commonly debated escalation strategy. Further research can examine whether other thresholds or more individualized decisions produce benefits that this comparison did not demonstrate.